Originalartikel | erschienen - Druck | peer reviewed
Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study.
NEPHROLOGY DIALYSIS TRANSPLANTATION
2022 ;
37(12):
2496 - 2504
Bibliometrische Indikatoren
Impact Factor = 6,1
Zitierhäufigkeit nach WOS = 19
DOI = 10.1093/ndt/gfac006
PubMed-ID = 35022790
Autoren
Jan Boeckhaus*, Julia Hoefele, Korbinian M Riedhammer, Mato Nagel, Bodo B Beck, Mira Choi, Maik Gollasch1, Carsten Bergmann, Joseph E Sonntag, Victoria Troesch, Johanna Stock, Oliver Gross
Beteiligte Einrichtungen
Abstract
Angiotensin-converting enzyme inhibitors (ACEis) have evolved as a first-line therapy for delaying end-stage renal failure (ESRF) in Alport syndrome (AS). The present study tested the hypothesis of a superior nephroprotective potential of an early ACEi intervention, examining a cohort with the COL4A5 missense variant p.(Gly624Asp).
Veröffentlicht in
NEPHROLOGY DIALYSIS TRANSPLANTATION
| Jahr | 2022 |
| Impact Factor (2022) | 6,1 |
| Volume | 37 |
| Issue | 12 |
| Seiten | 2496 - 2504 |
| Open Access | nein |
| Peer reviewed | ja |
| Artikelart | Originalartikel |
| Artikelstatus | erschienen - Druck |
| DOI | 10.1093/ndt/gfac006 |
| PubMed-ID | 35022790 |
Allgemeine Daten zur Fachzeitschrift
Kurzbezeichnung: NEPHROL DIAL TRANSPL
ISSN: 0931-0509
eISSN: 1460-2385
Land: ENGLAND
Sprache: English
Kategorie(n):
Impact Factor Entwicklung
ISSN: 0931-0509
eISSN: 1460-2385
Land: ENGLAND
Sprache: English
Kategorie(n):
- UROLOGY & NEPHROLOGY
- TRANSPLANTATION
Impact Factor Entwicklung
| Jahr | Impact Factor |
|---|---|
| 2008 | 3,568 |
| 2009 | 3,306 |
| 2010 | 3,564 |
| 2011 | 3,396 |
| 2012 | 3,371 |
| 2013 | 3,488 |
| 2014 | 3,577 |
| 2015 | 4,085 |
| 2016 | 4,47 |
| 2017 | 4,6 |
| 2018 | 4,198 |
| 2019 | 4,531 |
| 2020 | 5,992 |
| 2021 | 7,186 |
| 2022 | 6,1 |
| 2023 | 4,8 |
FAQs | Impressum | Datenschutz